# Celularity

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/celularity

- Industry: Biotechnology
- Headquarters: Florham Park, US
- Total disclosed funding: $250M
- Latest round: Series B (Feb 15, 2018)
- Investors on record: 8

## About

Based in New Jersey, US, and founded in 2016, Celularity, Inc. develops transformative allogeneic cellular therapies. The company was co-founded by Peter Diamandis and Robert Hariri, it's Chairman and CEO. In March 2023, Celularity, Inc. raised USD 6 million in PIPE funding.

The company develops placenta-derived allogeneic cell therapies for cancer, infectious, and degenerative diseases. Celularity's product targets multiple diseases, and provides seamless integration, from bio-sourcing through manufacturing cryopreserved and packaged allogeneic cells.

## Funding rounds

- Series B, Feb 15, 2018, $250M — Unither Pharmaceuticals, Louis-Dreyfus Family Office, Heritage Group, Bristol-Myers Squibb Company, Human Longevity, Inc., Section 32, Sorrento Therapeutics, Inc., Genting Ventures

## Investors

- Unither Pharmaceuticals — Series B
- Louis-Dreyfus Family Office — Series B
- Heritage Group — Series B
- Bristol-Myers Squibb Company — Series B
- Human Longevity, Inc. — Series B
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series B
- Sorrento Therapeutics, Inc. — Series B
- Genting Ventures (https://capitalatlas.ai/funds/genting-ventures) — Series B